Clinical trials: CKD Stage 3
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
This Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy and safety of daprodustat administered three-times weekly compared to epoetin alfa, the current standard of care.
- Trial name
- NCT03400033
- Testing
- Daprodustat tablets, Epoetin alfa vials, Saline vials or bags
- Where
- 91 sites in United States, Argentina and 11 more
- Volunteers
- 407 people
- Sponsor
- GlaxoSmithKline
Anemia, Dialysis-Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with dialysis-dependent chronic kidney disease (DD-CKD)
- Trial name
- NCT02892149
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 278 sites in United States, Argentina and 16 more
- Volunteers
- 3,554 people
- Sponsor
- Akebia Therapeutics
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood.
- Trial name
- ALPS (NCT01887600)
- Testing
- Roxadustat
- Where
- 138 sites in Belarus, Belgium and 20 more
- Volunteers
- 594 people
- Sponsor
- Astellas Pharma Europe B.V.
Anemia, Dialysis-Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).
- Trial name
- NCT02865850
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 118 sites in United States, Argentina and 9 more
- Volunteers
- 369 people
- Sponsor
- Akebia Therapeutics
Anemia
An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)
This observational study will evaluate the use and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in anemia patients with chronic kidney disease (CKD) stage III-IV not on dialysis or CKD stage V on dialysis.
- Trial name
- NCT01667380
- Where
- Montenegro
- Volunteers
- 78 people
- Sponsor
- Hoffmann-La Roche
Renal Insufficiency, Chronic, Iron-Deficiency Anemia
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
- Trial name
- AEGIS-CKD (NCT02968368)
- Testing
- Ferric maltol
- Where
- 27 sites in United States
- Volunteers
- 167 people
- Sponsor
- Shield Therapeutics
Anemia
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis
- Trial name
- NCT02174627
- Testing
- Roxadustat
- Where
- 359 sites in United States, Argentina and 24 more
- Volunteers
- 2,781 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate)
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
An open-label, phase IB, multi-center study evaluating DM199 in subjects with Type 1 Diabetes or Type 2 Diabetes and Stage 3 or 4 Chronic Kidney Disease.
- Conditions
- Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
- Trial name
- NCT03795389
- Testing
- DM199
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- DiaMedica Therapeutics Inc